Association of Body Mass Index With Cardiometabolic Disease in the UK Biobank
A Mendelian Randomization Study

Donald M. Lyall, PhD; Carlos Celis-Morales, PhD; Joey Ward, BSc; Stamatina Iliodromiti, MD; Jana J. Anderson, PhD; Jason M. R. Gill, PhD; Daniel J. Smith, PhD; Uduakobong Efanga Ntuk, PhD, MSc; Daniel F. Mackay, PhD; Michael V. Holmes, MD, PhD; Naveed Sattar, MD, PhD; Jill P. Pell, MD

**IMPORTANCE** Higher body mass index (BMI) is a risk factor for cardiometabolic disease; however, the underlying causal associations remain unclear.

**OBJECTIVES** To use UK Biobank data to report causal estimates of the association between BMI and cardiometabolic disease outcomes and traits, such as pulse rate, using mendelian randomization.

**DESIGN, SETTING, AND PARTICIPANTS** Cross-sectional baseline data from a population-based cohort study including 119,859 UK Biobank participants with complete phenotypic (medical and sociodemographic) and genetic data. Participants attended 1 of 22 assessment centers across the United Kingdom between 2006 and 2010. The present study was conducted from May 1 to July 11, 2016.

**MAIN OUTCOMES AND MEASURES** Prevalence of hypertension, coronary heart disease, and type 2 diabetes were determined at assessment, based on self-report. Blood pressure was measured clinically. Participants self-reported sociodemographic information pertaining to relevant confounders. A polygenic risk score comprising 93 single-nucleotide polymorphisms associated with BMI from previous genome-wide association studies was constructed, and the genetic risk score was applied to derive causal estimates using a mendelian randomization approach.

**RESULTS** Of the 119,859 individuals included in the study, 56,816 (47.4%) were men; mean (SD) age was 56.87 (7.93) years. Mendelian randomization analysis showed significant positive associations between genetically instrumented higher BMI and risk of hypertension (odds ratio [OR] per 1-SD higher BMI, 1.64; 95% CI, 1.48-1.83; \( P = 1.1 \times 10^{-19} \)), coronary heart disease (OR, 1.35; 95% CI, 1.09-1.69; \( P = .007 \)) and type 2 diabetes (OR, 2.53; 95% CI, 2.04-3.13; \( P = 1.5 \times 10^{-17} \)), as well as systolic blood pressure (\( \beta = 1.65 \text{ mm Hg}; 95\% \text{ CI}, 0.78-2.52 \text{ mm Hg}; P = 2.0 \times 10^{-04} \)) and diastolic blood pressure (\( \beta = 1.37 \text{ mm Hg}; 95\% \text{ CI}, 0.88-1.85 \text{ mm Hg}; P = 3.6 \times 10^{-08} \)). These associations were independent of age, sex, Townsend deprivation scores, alcohol intake, and smoking history.

**CONCLUSIONS AND RELEVANCE** The results of this study add to the burgeoning evidence of an association between higher BMI and increased risk of cardiometabolic diseases. This finding has relevance for public health policies in many countries with increasing obesity levels.

Published online July 5, 2017.

© 2017 American Medical Association. All rights reserved.
Obesity is a major public health concern in terms of economic costs and effect on quality of life and health. A total of 40% of adults worldwide are overweight, with a body mass index (BMI) of 25 or more (calculated as weight in kilograms divided by height in meters squared), and 13% are obese (BMI 30). Higher BMI is a risk factor for outcomes associated with lower quality of life and functional impairment, including cardiometabolic diseases such as hypertension, coronary heart disease (CHD), type 2 diabetes, stroke, and cognitive impairment. Although lifestyle factors are considerable drivers of excess adiposity, BMI has a significant genetic component: approximately 34% of BMI variation can be attributed to common genetic loci.7

Correlations between higher BMI and cardiometabolic disease risk usually arise from observational studies that are unable to fully account for confounding by shared risk factors, such as socioeconomic deprivation, or reverse causality whereby the presence of disease may influence BMI.8 Mendelian randomization (MR) is an approach that partially overcomes these limitations. In instances where genetic risk factors for a trait (eg, BMI) have been reported, these can be used to proxy lifetime variation of the trait and facilitate analysis of whether the trait plays a causal role in disease risk through instrumental variable analysis.9

Studies by Nordestgaard et al10 (N = 75 627), Holmes et al11 (N = 34 548), and Hägge et al12 (N = 22 193) compared observational with causal estimates of the association of BMI with CHD, stroke, and type 2 diabetes. The investigators reported discrepant results first in terms of observational vs causal estimate odds ratios (ORs) and showed inconsistency in terms of finding significant associations with CHD and stroke.

The conflicting evidence as to whether a true association exists between BMI and cardiometabolic diseases and, if so, the magnitude of that association lends support to adopting an MR approach to investigating whether BMI has a causal relationship with a range of important phenotypes related to health in a large biobank.10,11 The present study used UK Biobank (n = 119 859 with usable data). Our report advances the field in 3 important ways: (1) by including a relatively large sample size in a single study with detailed measurement of covariates (eg, smoking history); (2) by using a 93 single-nucleotide polymorphism (SNP) polygenic risk (PGR) score based on a genome-wide association study of 339 224 individuals, with 56 recent discoveries13; and (3) by conducting MR of BMI on a range of outcomes, including CHD, type 2 diabetes, hypertension, and stroke as well as blood pressure (BP) and pulse rate, the latter two being easily and commonly assessed noninvasive variables that are prognostic for cardiovascular outcomes.14

Methods

Study Design and Participants
The UK Biobank cohort is a large prospective cohort of 502 628 participants with phenotypic information. In the present analysis, we report on cross-sectional data at baseline. All participants attended 1 of 22 assessment centers from 2006 to 2010 where they completed a series of physical, sociodemographic, and medical assessments.15,16 In total, 152 729 participants currently have genetic data. This study was conducted from May 1 to July 11, 2016, under generic approval from the UK National Health Service National Research Ethics Service. Participants provided written informed consent.

Exclusions
Of 152 729 UK Biobank participants who were genotyped, we first excluded nonwhite European participants (based on self-report), leaving 137 178 individuals. We then removed participants who had a relatedness coefficient above 0.0442 (eg, first cousins), mismatch between reported and genetic sex, or failed UK Biobank quality controlling and were recommended exclusions (by UK Biobank), resulting in a final sample of 119 859 individuals.

Physical Traits
Participants were asked during the baseline assessment about any previous or current cardiometabolic conditions that had been diagnosed by their physician. Specifically, participants were asked whether their physician had diagnosed myocardial infarction, angina, hypertension, or stroke. We defined CHD as either myocardial infarction or angina (the results were similar when we analyzed myocardial infarction individually). We excluded participants who stated only “prefer not to answer” (170 [0.14%] of the total to this multiple-choice question). Participants were separately asked whether their physician had diagnosed diabetes. A minority may have had type 1 rather than type 2 diabetes. We removed participants with missing data for this question (259 [0.22%]). Because UK Biobank is nationally representative of the United Kingdom, we would expect most strokes to be ischemic.17

Height was measured (seca 202 stadiometer; seca) and weight was measured to the nearest 0.1 kg (BC-418 MA body composition analyzer; Tanita Corp). Body mass index was derived from weight in kilograms divided by height in meters squared. Participants self-reported their sex and age; stated their smoking status as never, previous, or current; and reported their alcohol intake as never, special occasions only, 1 to 3 times a month, once or twice a week, 3 or 4 times a week, and daily or almost daily. Alcohol intake and smoking status were treated as ordinal variables after removing participants.
who preferred not to answer and for whom their alcohol/smoking status was therefore ambiguous; the low missing numbers of 77 (0.1%) for alcohol and 320 (0.3%) for smoking are unlikely to bias the results meaningfully. Blood pressure and pulse rate were assessed using digital blood pressure monitors (HEM-7015IT; Omron Healthcare Inc). We used the first reading because it had the largest sample size. There was a significant reduction in systolic BP from the first to second measurement (mean [SD], 139.9 [19.69] and 136.0 [18.65] mm Hg; P < .001; Cohen d = 0.20, which represents a small effect size), but not for diastolic BP (82.2 [10.7] and 82.2 [10.2] mm Hg; P = .81; Cohen d = < 0.01). Both diastolic and systolic BPs first and second readings correlated at r = 0.9 (P < .001). The results were unchanged when we ran analyses on the subset of individuals with available measurements from second readings only or a mean of first and second readings. Participants self-reported estimated physical activity, which was summed to create an overall physical activity score. Participants were asked whether they were receiving any antihypertensive medication during an on-screen assessment with response options of yes, no, or don’t know. Those who did not know were removed from analysis (242 [0.20%]), and we adjusted for yes/no status of self-reported antihypertensive medication use in all BP and pulse rate analyses as an additional covariate. Participants self-reported their ethnicity and we recoded this as a white European vs other ethnicity variable. A Townsend deprivation score (minimum, −6.26; maximum, 10.78; mean [SD], −1.47 [3.00]) for all participants was derived. Higher Townsend scores equate to higher levels of area-based socioeconomic deprivation.

Genetic Data
UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom array for 49 979 participants and on a further updated bespoke Affymetrix Axiom array for the remaining 102 750 individuals in this study, based on the first array. The 2 arrays are very similar, sharing more than 95% marker content. We controlled for array type as a covariate. Further information on the genotyping process is available on the UK Biobank website (http://www.ukbiobank.ac.uk/scientists-3/genetic-data), which includes detailed technical documentation.20 There were 33 genetic batches: II BiLEVE and 22 UK Biobank. Approximately 4000 to 5000 participants were in each batch, and they are described in the above-referenced documentation.20(20) We followed UK Biobank recommendations on which participants to exclude from analysis based on whether the sample failed quality control and had significant missing data or heterozygosity. We used 10 UK Biobank–provided genetic principal components to account for population stratification.

Results were similar when we ran analyses unadjusted for these 10 principal components. All SNPs had a missingness rate lower than 1%, except for rs10733682 (8%), although the results were unchanged with or without inclusion of this SNP. We therefore report results with this SNP included. The PGR score was derived from 97 SNPs associated with BMI at genome-wide significance in a previous study of more than 339 224 participants of European descent13 (eTable 1 in the Supplement). Of these, 95 SNPs were directly genotyped in UK Biobank. Two SNPs failed in Hardy-Weinberg equilibrium20 (rs9925964 and rs17001654; P < 1 × 10−6) as assessed with PLINK, and were excluded, leaving 93 SNPs for the BMI genetic instrument.21 We constructed an externally weighted PGR score for each participant, weighted by the effect estimates reported in GIANT (β per 1-SD unit of BMI).21

Statistical Analysis
For all analyses, in the partially adjusted model we adjusted for assessment center, age, sex, genetic batch effects, array, and stratification with the 10 genetic principal components. In the fully adjusted model, Townsend deprivation scores, smoking status, and alcohol intake were added as covariates. All statistical tests were 2-sided and P < .01 denoted nominal significance. A conservative P value was chosen as we had multiple outcomes; formal correction for type I error can be overly conservative when testing intercorrelated outcomes.22 Stata, version 13,23 was used for all analyses.

Observational Analysis
For the observational analyses of BMI association with various binary disease traits, we report logistic regression ORs and 95% CIs. Continuous traits are reported as unstandardized β values with linear regression.

MR Analysis
We used 2 MR approaches. First, we ran conventional MR using individual-level data to conduct 2-stage least squares analysis for continuous trait data (using Stata command ivreg224,25) and control function estimator for binary traits.26 We used robust SE variances throughout and MR-Egger for the second MR method. MR-Egger is a linear regression of estimated SNP effects for the risk allele on exposure against the corresponding estimates of SNPs on outcome weighted by the inverse variance of the SNP on outcome effect estimates. The regression line in MR-Egger is not forced through the origin, and the presence of unbalanced horizontal pleiotropy (ie, where the SNPs are associated with alternative pathways to the exposure that have independent effects on the outcome) can be inferred from an intercept that differs from zero.27 While the inclusion of pleiotropic SNPs can bias causal estimates and increase the rate of false positives (ie, type I errors) or introduce bias to the null, MR-Egger can bypass this by showing evidence of pleiotropy in the instrument (the PGR score) and providing a causal estimate (making certain assumptions) that is robust to such pleiotropy. For MR-Egger, we used the same covariate models as the previous analyses. We conducted checks to support the validity of the MR analysis using multiple genetic variants (ie, the 93-SNP PGR score) as follows. Possible pleiotropy for each of the 93 SNPs can be assessed visually by a scatterplot, where each point should be roughly visually compatible with a linear function. This linearity ideally reflects homogeneity of causal estimates from different genetic variants; the eFigure in the Supplement shows a scatterplot of these variants for each outcome (eg, CHD) vs genetic associations with BMI, adjusted for age and sex. There was 1
outlier each for type 2 diabetes (rs7903146), systolic BP (rs191560), and diastolic BP (rs13107325); the results were unchanged when these outliers were removed and, for simplicity, we report estimates derived using all 93 SNPs.

Results

Descriptives

Of the 119 859 participants who satisfied the inclusion criteria (eg, passed quality control as described in the Genetic Data section), the mean (SD) age was 56.87 (7.93) years, and 56 816 (47.4%) of the population were men. The mean (SD) BMI in this 119 859 subset of the UK Biobank was 27.53 (4.83), which was similar to the BMI for the entire cohort (N = 449 472 with BMI data mean = 27.43, SD = 4.80). Descriptive statistics are reported in Table 1.

Observational Analysis BMI and Outcome Variables

In the fully adjusted models (Table 2), an SD increase in BMI (4.83 kg/m²) was associated with the risk of stroke (OR, 1.26; 95% CI, 1.21-1.31; P = 2.0 × 10⁻²⁰), CHD (OR, 1.43; 95% CI, 1.40-1.46; P = 2.0 × 10⁻¹⁸⁴), hypertension (OR, 1.75; 95% CI, 1.73-1.78; P < 4.51 × 10⁻³⁰⁸), and type 2 diabetes (OR, 1.97; 95% CI, 1.93-2.02; P < 4.51 × 10⁻³⁰⁸). In addition, BMI was associated with higher systolic BP (β = 3.02 mm Hg; 95% CI, 2.91-3.13 mm Hg; P < 4.5 × 10⁻³⁰⁸), diastolic BP (β = 2.82 mm Hg; 95% CI, 2.76-2.89 mm Hg; P < 4.5 × 10⁻³⁰⁸), and pulse rate (β = 1.86 beats/min; 95% CI, 1.79-1.94 beats/min; P < 4.5 × 10⁻³⁰⁸).

MR Assumptions

The first MR assumption is that the polygenic score is associated with the exposure under investigation (BMI), and this is supported by the data (Pearson r = 0.14, P < 4.51 × 10⁻³⁰⁸; r² = 2% variance in BMI explained; F statistic = 2175). The second MR assumption is that SNPs associate with disease risk only through the instrumented variable (BMI here), and the third MR assumption is that the genetic variants do not show association with traits that can confound the BMI to disease relationships.

The second and third MR assumptions may be violated when the SNPs employed in the genetic instrument show associations with variables (eg, smoking) which could influence the SNP to outcome association. Such so-called pleiotropy can be either vertical (ie, reflecting an association of SNPs with traits on the same pathway from exposure through to outcome, eg, in this case an association of BMI SNPs with systolic BP on the pathway to CHD, or horizontal (ie, on pathways that are distinct to the one from exposure through to outcome). Directional (also termed unbalanced) horizontal pleiotropy can lead to biased causal estimates from MR (see Figure 1 in White et al28 for a recent pictorial description of vertical and balanced/unbalanced horizontal pleiotropy).27 eTable 2 in the Supplement shows correlations between the BMI PGR score with smoking status (Pearson r = 0.02; P < .001), Townsend score (r = 0.01; P = .02), and alcohol intake (r = 0.03; P < .001). It is unclear whether these results reflect vertical (ie, downstream of BMI) or rather horizontal (ie, genetic associations with traits that are on separate pathways to BMI) pleiotropy.29 If these associations with smoking, deprivation, and alcohol were to lead to directional horizontal pleiotropy, the intercept from MR-Egger would be expected to differ from zero; in such cases that we found evidence that the intercept was different to zero, we interpreted the coefficient from MR-Egger as being the more valid causal estimate. Conversely, in the absence of statistical evidence for horizontal pleiotropy from the intercept on MR-Egger, we used the conventional MR analysis as it retains greater power.

MR Analysis of BMI and Outcomes

Mendelian randomization analyses (Table 3) using individual participant data showed generally similar effect sizes compared with observational analyses for hypertension (OR, 1.64; 95% CI, 1.48-1.83; P = 1.1 × 10⁻¹⁹) and CHD (OR, 1.35; 95% CI, 1.09-1.69; P = .007). The association with type 2 diabetes increased in magnitude from the association noted on observational analysis (OR, 1.97; 95% CI, 1.93-2.02; to OR, 2.53; 95% CI, 2.04-3.13). There was no association of BMI with stroke on MR analysis (P = .93). The Figure shows the causal estimate ORs vs the observational estimates for disease outcomes. Use of MR-Egger analyses did not identify evidence of unbalanced horizontal pleiotropy (eTables 3 and 4 in the Supplement). Associations with systolic/diastolic BP remained significant, but

---

Table 1. Baseline Characteristics of Participants From UK Biobank Used in the Analysis

<table>
<thead>
<tr>
<th>Variable</th>
<th>Participants (n = 119 859)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>56.87 (7.93)</td>
</tr>
<tr>
<td>Male, No. (%)</td>
<td>56 816 (47.4)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>27.53 (4.83)</td>
</tr>
<tr>
<td>Smoking history, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>63 840 (53.26)</td>
</tr>
<tr>
<td>Past</td>
<td>41 026 (34.23)</td>
</tr>
<tr>
<td>Current</td>
<td>14 673 (12.24)</td>
</tr>
<tr>
<td>Missing</td>
<td>320 (0.27)</td>
</tr>
<tr>
<td>Alcohol intake, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>25 772 (21.46)</td>
</tr>
<tr>
<td>Special occasions only</td>
<td>28 074 (23.42)</td>
</tr>
<tr>
<td>1-3 Times/mo</td>
<td>31 249 (26.07)</td>
</tr>
<tr>
<td>1-2 Times/wk</td>
<td>13 420 (11.20)</td>
</tr>
<tr>
<td>3 or 4 Times/wk</td>
<td>13 160 (10.98)</td>
</tr>
<tr>
<td>Daily or almost daily</td>
<td>8152 (6.80)</td>
</tr>
<tr>
<td>Missing</td>
<td>77 (0.06)</td>
</tr>
<tr>
<td>Disease prevalence rates, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>1958 (1.6)</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>5764 (4.8)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>32 874 (27.5)</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>6290 (5.3)</td>
</tr>
<tr>
<td>Assessed physical traits, mean (SD)</td>
<td></td>
</tr>
<tr>
<td>Systolic BP, mm Hg</td>
<td>140.28 (19.70)</td>
</tr>
<tr>
<td>Diastolic BP, mm Hg</td>
<td>82.31 (10.64)</td>
</tr>
<tr>
<td>Pulse rate, beats/min</td>
<td>69.68 (11.77)</td>
</tr>
<tr>
<td>Receiving BP-related medication, No. (%)</td>
<td>11 167 (9.3)</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure.
Additional Analyses

As a check, we also repeated the analysis of type 2 diabetes, CHD, and hypertension results after removing participants who reported their age at diagnosis as unknown, chose not to answer, or age at diagnosis 10 years or younger (cases removed: 238 for type 2 diabetes, 229 for CHD, and 3155 for hypertension); findings were unchanged. Including physical activity in the final models made no difference to the final results.

Discussion

Using the UK Biobank cohort, we examined the causal effects of BMI, using a genetic risk score comprising 93 SNPs associated with BMI, \(9,10\) on important cardiometabolic traits and outcomes. The main advantage of an MR approach is that certain types of study bias can be minimized. Because DNA is stable and randomly inherited, which helps to mitigate errors from reverse causality and confounding, genetic variation can be used as a proxy for lifetime BMI to overcome limitations such as reverse causality and confounding, \(9,10\) a process that hampers observational analyses of obesity and its consequences.

Using MR in the UK Biobank, we found that higher BMI was associated with a range of deleterious outcomes based on causal MR estimates: increased risk of CHD (causal estimate OR, 1.35; 95% CI, 1.09-1.69; per-SD [4.8-unit] increase in BMI), hypertension (OR, 1.64; 95% CI, 1.48-1.83), and type 2 diabetes (OR, 2.53; 95% CI, 2.04-3.13), as well as increased blood pressure (\(\beta = 1.65\) mm Hg; 95% CI, 0.78-2.52 mm Hg systolic; and \(\beta = 1.37\); 95% CI, 0.88-1.85 mm Hg diastolic). However, there were no causal effects on pulse rate or stroke identified. Associations were independent of Townsend deprivation scores, alcohol intake, smoking status, age, sex, and antihypertensive medication.

Three previous studies have provided causal estimates of BMI and cardiometabolic diseases based on polygenic instruments. \(10-12\) Studies have reported their ORs and effect sizes in different scales, eg, per 1-unit of BMI (Holmes et al\(10\)), per 4-units of BMI (Nordestgaard et al\(11\)), and per 4.8 (this study; equivalent to one standard deviation). In terms of CHD: Nordestgaard et al\(10\) reported an OR of 1.28 per 4 units of BMI.
on risk of CHD (N = 75,627) and Holmes et al\textsuperscript{11} reported an OR of 1.04 (in a meta-analysis of 219,423 participants) per 1-unit of BMI (an OR of 1.17 when scaled to a 4-unit increase in BMI as per Nordestgaard et al\textsuperscript{10} or OR of 1.21 in our study where 1 SD equaled 4.8 units of BMI). Hägg et al\textsuperscript{12} reported no association for incident CHD (hazard ratio [HR], 1.13; P = .62), per 4.5 units of BMI. We report an OR of 1.35 per SD of BMI on the risk of CHD, similar to that of Nordestgaard et al\textsuperscript{10}. In terms of type 2 diabetes: Holmes et al\textsuperscript{11} reported an association with type 2 diabetes (OR, 1.29 per unit of BMI or 2.77 extrapolated to 4 units of BMI as per Nordestgaard et al\textsuperscript{10}), which is also similar to our results (OR, 2.53). The BMI and type 2 diabetes association estimates were larger for the causal MR analyses (OR in fully adjusted models, 2.53; 95\% CI, 1.93-3.13) vs observational (OR, 1.97; 95\% CI, 1.93-2.02). This is often the case in MR analyses since the genetic instrument represents a lifelong exposure to a risk factor and minimizes regression dilution bias.\textsuperscript{28} It is not clear why Hägg et al\textsuperscript{12} found a significant association with stroke (HR, 1.83; P = .03) in their study, and we did not in UK Biobank.

Studies by Fall et al\textsuperscript{30} (N = 198,502) and Timpson et al\textsuperscript{31} (N = 37,027, specifically investigating BP/hypertension) showed similar results using a single SNP in the FTO locus as an instrumental variable. In contrast to previous studies, we used a 93-SNP PGR score and corrected for population stratification with 10 principal components: these factors may contribute to slight differences between studies, but, on the whole, findings are generally concordant. Our PGR score used many more SNPs (appropriate given that BMI is not encoded for by any single variant in isolation) compared with the 2 previous studies,\textsuperscript{30,31} meaning that our genetic instrument explained a greater proportion of variance of BMI, which increased the precision of and power to detect the causal estimates that we report. Holmes et al\textsuperscript{11} summarized 4 large studies that conducted MR on BMI (N = 219,423), where the instrument \( r^2 \) range was 0.4\% to 0.8\%; our instrument explained 1.79\% of the variance. Taken together, our data provide strong evidence for a causal role of higher BMI and risk of type 2 diabetes and hypertension, and evidence that BMI increases risk of CHD.

Limitations

There are some limitations to the present report. There may be a degree of selection bias in the sense that less physically and cognitively impaired individuals responded to the UK Biobank invitation and attended the assessment.\textsuperscript{31} The UK Biobank cohort is representative of the UK population in terms of some characteristics, such as age, sex, ethnicity, and deprivation, but not necessarily all (eg, some participants are less likely to smoke and drink alcohol regularly).\textsuperscript{32} That said, the disease rates were similar to those reported in the British Heart Foundation 2015 report for hypertension (31\% for men and 26\% for women vs 27.5\% in the present study), type 2 diabetes (6.9\% for men and 5.6\% for women vs 5.3\%),\textsuperscript{33} and in the Health Survey for England 2014 report on data for CHD (5\% vs 4.8\%) and stroke (2\% vs 1.6\%).\textsuperscript{34} We found a small but significant correlation between the PGR score and higher rates of smoking, alcohol intake, and Townsend deprivation scores and thus made additional adjustments for these factors in our analyses, which did not alter the estimates we obtained. As described above, whether these associations represent vertical or horizontal pleiotropy remains unknown. The present sample also lacks data on a complete repertoire of potential mediators, such as lipid traits and glucose levels; these data will be available in the full UK Biobank in the next few years (along with genetic data on the total sample of 502,628 individuals in 2017). Because the MR-Egger analyses did not provide evidence to suggest presence of unbalanced horizontal pleiotropy, we have discussed the results in terms of conventional MR analytical approaches. It should be noted, however, that evidence for a causal BMI association with CHD and systolic/diastolic BP would be significantly weakened based on the MR-Egger estimates (to \( P > .05 \)). Because MR-Egger is inherently more conservative, potentially meaningful causal associations might not be identified (type II error). Furthermore, this approach may be inadequately powered to detect pleiotropy when it is present.

Our analysis focused on prevalent disease. Although this should not result in major bias, the UK Biobank data set includes linkage to National Health Service records and hospital admissions data. During 4.9 years of follow-up from baseline, 3,433 incident cardiovascular events occurred (including CHD).\textsuperscript{35} This finding was based on the full baseline data set of 502,649 participants, whereas genetic data are available on only 119,859 individuals, resulting in approximately 1000 incident events in the current data set. We will investigate genetically estimated BMI and cardiovascular events (eg, myocardial infarction and onset of hypertension, diabetes, and stroke) when genetic data are available on the full data set in 2017.

In terms of mechanisms, Holmes et al\textsuperscript{11} reported that a BMI PGR score based on 14 SNPs was associated with known cardiovascular risk factors, including glycemic traits, inflammation, and higher systolic and diastolic BPs. It seems a reasonable hypothesis that BMI would increase the risk of diseases through these established causal risk factors for CHD; the UK Biobank serum
biomarker data are not yet available; however, we will investigate the role of these potentially mediating variables in the future. In terms of public health, with 39% and 13% of adults overweight or obese, respectively, and cardiovascular disease remaining the leading cause of mortality globally, our data emphasize the role of BMI, a modifiable risk factor, in cardiometabolic disease and the importance of reducing BMI at a population level to lower the incidence of cardiometabolic disease.

Conclusions

We report that BMI increases the risk of CHD, hypertension, type 2 diabetes, and diastolic and systolic BPs based on causal MR estimates. Body mass index represents an important modifiable risk factor for ameliorating the risk of cardiometabolic disease in the general population.

ARTICLE INFORMATION

Accepted for Publication: November 26, 2016.
Published Online: July 5, 2017. doi:10.1001/jamacardio.2016.3804

Author Contributions: Drs Holmes, Sattar, and Pell contributed equally to the study. Dr Lyall had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Lyall, Sattar, Holmes. Acquisition, analysis, or interpretation of data: Lyall, Celis-Morales, Ward, Widdicombe, Anderson, Gill, Ntuk, Mackay, Holmes, Pell. Drafting of the manuscript: Lyall. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Lyall. Obtained funding: Pell. Administrative, technical, or material support: Celis-Morales, Ward, Smith. Study supervision: Sattar, Pell, Holmes.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Sattar and Pell are members of UK Biobank scientific committees. This conflict of interest did not affect the present study with regard to motivation, analysis, or interpretation. No other disclosures were reported.

Funding/Support: This research received funding from the Welsh Assembly Government and the British Heart Foundation.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We are grateful to UK Biobank participants.

Additional Information: This research was conducted using UK Biobank application 7155. UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council (MRC), Department of Health, Scottish Government and the Northwest Regional Development Agency.

REFERENCES


Harnessing Genomic Biobanks to Understand Obesity in Cardiometabolic Disease
Prospects and Pitfalls

Christopher J. O’Donnell, MD, MPH

Deep genome-wide profiling has increasingly become a standard measurement in established cardiovascular population cohorts and in emerging precision medicine biobanks. In this issue of JAMA Cardiology, Lyall et al1 harness genetic and clinical information from the UK Biobank to demonstrate a causal association between elevated body mass index (BMI) and increased risks for hypertension, type 2 diabetes, and coronary heart disease (CHD). Mendelian randomization (MR) analysis requires triangulation of 3 associations: gene variants and BMI, BMI and cardiometabolic disease, and BMI gene variants and cardiometabolic disease. The MR approach takes advantage of natural randomization at birth to germline genotypes that are robustly associated with BMI and are selected as BMI proxies (“instrumental variables”). Because the instrumental variable is an unconfounded marker of BMI over the lifecourse, MR protects against confounding by reverse causality. For the instrumental variable, a genetic risk score was used of 97 genetic variants reported in the largest genome-wide association study for BMI.2 Using MR analysis, the authors report significant “causal” associations of BMI with hypertension (odds ratio, 1.64; 95% CI, 1.48-1.83), type 2 diabetes (odds ratio, 2.53; 95% CI, 2.04-3.13), and CHD (odds ratio, 1.35; 95% CI, 1.09-1.69) but not stroke, even after use of a conservative (MR-Egger) approach.

Prior MR studies have supported (eg, for low-density lipoprotein cholesterol or lipoprotein[a]) or refuted (eg, for C-reactive protein or high-density lipoprotein cholesterol) evidence of risk factor causality with CHD. Strengths and limitations of the MR approach have been well described.3 A unique feature and strength of the current analysis is its conduct within a single mega-cohort, instead of meta-analysis of multiple different cohorts. Among the study limitations was the conduct of a cross-sectional rather than prospective association analysis of BMI with cardiovascular disease events.

In well-established cohorts, such as Framingham, BMI is clearly associated with both traditional risk factors and with CHD, but the association of BMI with CHD is nonsignificant after adjustment for other major modifiable risk factors. Of note, multivariable office-based cardiovascular disease risk prediction functions that incorporate BMI instead of lipid measures perform nearly as well in risk prediction.4 From a preventive cardiology perspective, the MR study of Lyall et al1 refocuses attention on, and strengthens the body of literature for, a “causal” connection of BMI with increasing blood pressure, diabetes, and CHD. Nevertheless, further research is needed to expand our understanding of mechanism from molecular genetic and/or interventional clinical studies. We invite reports of clinically relevant cardiovascular disease findings using well-designed genomic studies in large, well-phenotyped biobank cohorts as well as consortia of meta-analyzed cohorts, and we encourage studies that further our understanding of both causality and mechanisms of cardiovascular disease and health.